Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

PURPOSE: BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Abida, Wassim, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Loehr, Andrea, Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
RAPID COMMUNICATIONS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655021/
https://ncbi.nlm.nih.gov/pubmed/32795228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01035
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items